HUYABIO Announces HBI-8000 Brand Name of Hiyasta™
SAN DIEGO, June 24, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, announced today that HBI-8000 will be marketed under the brand name Hiyasta™ in Japan. Hiyasta was recently approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of adult T-cell leukemia/lymphoma (ATLL) as monotherapy.
Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO said, "Today's approval of Hiyasta for ATLL came in just 9 months. Our commercial partnership with Meiji will now bring Hiyasta to patients and provide much needed public health benefit for this devastating, life threatening disease."
Hiyasta was also submitted to the PMDA in March for approval as monotherapy to treat peripheral T-cell lymphoma (PTCL). In addition, the ODD designation for Hiyasta in Japan has been formally approved for both ATLL and PTCL.
About HUYABIO International
View original content to download multimedia:http://www.prnewswire.com/news-releases/huyabio-announces-hbi-8000-brand-name-of-hiyasta-301319129.html
SOURCE HUYABIO International